Goldman Ends Endo Coverage Following Q2 EBITDA Guide
NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide
One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.
You may also be interested in...
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.
China’s HEC Pharm, the last ANDA filer for fingolimod standing in patent litigation, has won a key invalidity challenge against a dosing-regimen patent shielding the multiple sclerosis treatment. However, the Federal Circuit was split on whether it had applied a heightened standard for negative claim limitations.